Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. 1982

L V Parise, and D L Venton, and G C Le Breton

The relative contribution of thromboxane (TX)A2/prostaglandin (PG)H2 and ADP to platelet shape change was determined using the specific TXA2/PGH2 antagonist, 13-azaprostanoic acid (13-APA) and the ADP antagonist, ATP. Shape change was induced in human platelet-rich plasma with doses of arachidonic acid (AA) or the PG endoperoxide analog U46619, which did not cause measurable ATP/ADP release. Pretreatment of platelet-rich plasma with 13-APA completely inhibited shape change to AA or U46619 but did not inhibit ADP-induced shape change. In contrast, ATP completely blocked shape change to ADP but not to AA or U46619. In addition, 13-APA and ATP also selectively reversed shape change. Thus, 13-APA added 1.5 min subsequent to AA or U46619 resulted in almost complete reversal of the shape change response. However, 13-APA did not reverse ADP-induced shape change. A similar selectivity was observed with ATP which reversed shape change to ADP but not to AA or U46619. These findings provide evidence that the interaction of TXA2/PGH2 with its receptor results in the direct stimulation of shape change independent of secreted ADP. Furthermore, maintenance of this shape change response appears to require continued occupation of the TXA2/PGH2 receptor.

UI MeSH Term Description Entries
D011449 Prostaglandin Endoperoxides Precursors in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. They are physiologically active compounds, having effect on vascular and airway smooth muscles, platelet aggregation, etc. Endoperoxides, Prostaglandin
D011450 Prostaglandin Endoperoxides, Synthetic Synthetic compounds that are analogs of the naturally occurring prostaglandin endoperoxides and that mimic their pharmacologic and physiologic activities. They are usually more stable than the naturally occurring compounds. Prostaglandin Endoperoxide Analogs,Prostaglandin Endoperoxide Analogues,Synthetic Prostaglandin Endoperoxides,Analogues, Prostaglandin Endoperoxide,Endoperoxide Analogues, Prostaglandin,Endoperoxides, Synthetic Prostaglandin
D011463 Prostaglandins H A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin H2.
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D013931 Thromboxanes Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. Thromboxane
D019796 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110) (15S)-Hydroxy-11 alpha, 9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic Acid,(15S)hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid,11 alpha,9 alpha-Epoxymethano PGH2,9,11-Dideoxy-11 alpha,9 alpha-epoxymethanoprostaglandin F2 alpha,9,11-Dideoxy-11 alpha,9-alpha-epoxymethano-PGF2 alpha,9,11-epoxymethano-PGH2,U-44619,U-46619,U44619,U46619,11 alpha,9 alpha Epoxymethano PGH2,9,11 epoxymethano PGH2,U 44619,U 46619

Related Publications

L V Parise, and D L Venton, and G C Le Breton
February 1991, The American journal of physiology,
L V Parise, and D L Venton, and G C Le Breton
July 1992, The Journal of pharmacology and experimental therapeutics,
L V Parise, and D L Venton, and G C Le Breton
January 1987, Federation proceedings,
L V Parise, and D L Venton, and G C Le Breton
July 1989, Biochimica et biophysica acta,
L V Parise, and D L Venton, and G C Le Breton
May 1993, Arerugi = [Allergy],
L V Parise, and D L Venton, and G C Le Breton
January 1990, Methods in enzymology,
L V Parise, and D L Venton, and G C Le Breton
November 1977, Prostaglandins,
L V Parise, and D L Venton, and G C Le Breton
October 1990, Biochemical pharmacology,
L V Parise, and D L Venton, and G C Le Breton
January 1992, Biochemical pharmacology,
L V Parise, and D L Venton, and G C Le Breton
December 1988, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!